SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS
FIELD OF THE INVENTION
The present invention is related to a compound of the general formula (I),

its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, polymorph, solvate, its combination with suitable medicament, its pharmaceutical composition, method of making of the compound, its use as MALT1 inhibitor, and its therapeutic utility in various pathological conditions.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of Indian Provisional Patent Application Nos. 201621026107, filed on 29th July 2016, 201621043859, filed on 22nd December 2016, and 201721009450 filed on 17th March 2017, the disclosures of which are incorporated herein by reference in their entirety for all purposes.
BACKGROUND OF THE INVENTION
The present invention relates to MALT1 (Mucosa Associated Lymphoid tissue lymphoma translocation protein-1) inhibitors. MALT1 is a crucial immunomodulatory protein. Studies in Bcl-10 (Ruland et al, Cell, 104, 33-42, 2001) and MALT1-deficient (Ruland et al., Immunity, 19, 749-58, 2003; Ruefli-Brassi et al., Science, 302, 1581-84, 2003) mice revealed the importance of MALT1 for transducing antigen receptor signals to the transcription factor NF-kB (WO 2009/065897). Additionally, identification of several chromosomal translocations that leads to the generation of constitutively active MALT1 (as in

the case of ABC ' DLBCL) or the identification of MALT1 fusion protein API-MALT1/IgH-MALT1 that leads to NF-kB activation independent of upstream stimulation (as in case of Malt type lymphomas) further highlight the importance of this protein in cancer.
MALT1 and its partner Bcl-10 bind to different members of CARD (caspase recruitment domain) containing CARMA (CARD containing Membrane associated guanylate kinase) family of proteins, depending on the cell lineage. The signalosome formed upon antigen receptor stimulation (via TCR or BCR pathway) in the lymphocytes involves CARMA1/CARD11, whereas CARD9 interacts with MALT1 downstream of Toll like or C-type lectin receptors. MALT1-Bcl-10 signalosome involving CARD10 links signalling via GPCR and NF-kB activation in non-immune cells (McAllister-Lucas et al., PNAS, 104, 139-44, 2007). CARD14 interacts with MALT1 (and Bcl-10) in the keratinocytes. Thus, MALT1 acts as a central protein that is involved in many diseases directly or indirectly involving the inflammatory transcription factor, NF- kB.
It has been reported that inhibitors of MALT1 proteolytic activity have antiproliferative activity against ABC type DLBCL lymphomas (Fontan et al., Cancer Cell, 22, 812-24, 2012; Nagel et al., Cancer Cell, 22, 825-37, 2012; Fontan et al., Clin Cancer Res, 19, 6662-68, 2013). Further, MALT1 has been reported to be involved in several disease pathologies, e.g., different types of oncological disorders such as lung adenocarcinoma (J iang et al., Cancer Research, 71, 2183-92, 2011; Pan et al., Oncogene, 1-10, 2015), breast cancer (Pan et al., Mol Cancer Res, 14, 93-102, 2016), mantle cell lymphoma (Penas et al., Blood, 115, 2214-19, 2010; Rahal et al., Nature Medicine, 20, 87-95, 2014), marginal zone lymphoma (Remstein et al., Am J Pathol, 156, 1183-88, 2000; Baens et al., Cancer Res, 66, 5270-77, 2006; Ganapathi et al., Oncotarget, 1-10, 2016; Bennett et al., Am J of Surgical Pathology, 1-7, 2016), cutaneous T cell lymphomas such as Sezary syndrome (Qin et al., Blood, 98, 2778-83, 2001; Doebbeling et al., J of Exp and Clin Cancer Res, 29, 1-5, 2010), primary effusion lymphoma (Bonsignore et al., Leukemia, 31, 614-24, 2017), pancreatic cancer (Patent WO2016193339A1), certain types of chronic lymphocytic leukemia with CARD11 mutation and also certain subtypes of GCB-DLBCL type of lymphomas that involve MALT1. Moreover, targeting an immunomodulatory

protein can have direct and indirect benefits in a variety of inflammatory disorders of multiple organs,for example, in treating psoriasis (Lowes et al, Ann Review Immunology, 32, 227-55, 2014; Afonina et al., EMBO Reports, 1-14, 2016; Howes et al., Biochem J , 1-23, 2016), multiple sclerosis (J abara et al., J Allergy Clin Immunology, 132, 151-58, 2013; McGuire et al., J of Neuroinflammation, 11, 1-12, 2014), rheumatoid arthritis, Sjogren's syndrome (Streubel et al., Clin Cancer Research, 10, 476-80, 2004; Sagaert et al., Modern Pathology, 19, 225-32, 2006), ulcerative collitis (Liu et al., Oncotarget, 1-14, 2016), MALT lymphomas of different organs (Suzuki et al., Blood, 94, 3270-71, 1999; Akagi et al., Oncogene, 18, 5785-94, 1999) and different types of allergic disorders resulting from chronic inflammation.
In addition, several patent applications realted to MALT1 are published which are as follows: WO 2008 146259, WO 2009 065897, WO 2013 017637, WO 2013 053765, WO 2014 074815, WO 2014 086478, WO 2014 207067, WO 2015 110406, WO 2015 181747, WO 2016 193339, WO 2017 040304, WO 2017 057695, and WO 2017 081641.
The foregoing shows that there exists an unmet need for MALT1 inhibitory compounds for treating diseases or disorders involving MALT1 activation, particularly cancers as well as inflammatory disorders that are dependent on the MALT1-NF-kB axis.
BRIEF SUMMARY OF THE INVENTION
The present invention provides compounds of the general formula (I), their pharmaceutically acceptable salts, tautomeric forms, stereoisomers, polymorphs, solvates, combinations with suitable other medicament or medicaments and pharmaceutical compositions thereof and use thereof in treating various diseases or disorders including cancers.


wherein, R1-R3 are described in detail below.The compounds of the present invention are potent inhibitors of MALT1.
According to one aspect of the present invention, there is provided a compound represented by the general formula (I), its tautomeric form, its stereoisomer, its polymorph, its solvate, its pharmaceutically acceptable salt, its combinations with suitable medicament and its pharmaceutical compositions, wherein, R1-R3 are described in detail below.
The present invention provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, and its stereoisomer, its polymorph, its solvate, its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder mediated through MALT1.
The present invention provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, its stereoisomer, its polymorph, its solvate, and its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder such as cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.
The present invention provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, its stereoisomer, its polymorph, its solvate, and its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder such as ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone

lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1, germ cell tumors and neoplasm involving plasma cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney, psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis, pancreatitis, rheumatic fever, or rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides, Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease, cystic fibrosis, and respiratory diseases involving lungs leading to respiratory distress and failure.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is related to a compound of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, its solvate, its combination with suitable one or more other medicaments, its pharmaceutical composition, method of making of the compound, its use as MALT1 inhibitor, and its therapeutic utility in treating, or ameliorating various pathological conditions. The compounds are of formula (I) below:


wherein,
R1 is selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, and cycloalkyl;
R2 is selected from -
a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted heterocyclyl, -OR4, -C(=O)OH, -SO2(alkyl), -C(=O)O(alkyl), -NR5R5a, -NR5C(=O)R6 'C(=O)R6, and 'C(=O)NR5R5a,
b) cycloalkyl or cycloalkyl substituted with 1 to 4 substituents independently selected from halogen, cyano, substituted or unsubstituted alkyl, -OR4, -C(=O)OH,-C(=O)O(alkyl), 'C(=O)R6 and 'C(=O)NR5R5a,
c) cycloalkenyl,
d) cyano,
e) substituted or unsubstituted aryl,
f) substituted or unsubstituted heteroaryl,
g) heterocyclyl or heterocyclyl substituted on either ring carbon atom or a ring
nitrogen atom and when it is substituted on ring carbon atom it is substituted
with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano,
substituted or unsubstituted alkyl, cycloalkyl, -OR4, -C(=O)OH, -C(=O)O-alkyl, -
C(=O)NR5N5a, -N(H)C(=O)(alkyl), -N(H)R5, and -N(alkyl)2, and when the
heterocycle group is substituted on a ring nitrogen, it is substituted with
substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -
SO2(alkyl), 'C(=O)R6, C(=O)O(alkyl), -C(=O)N(H)R5, and -C(=O)N(alkyl)R5, and

h) -NRaRb, wherein, Ra and Rb are independent selected from hydrogen, cycloalkyl, and alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cycloalkyl, -OR4, and substituted or unsubstituted aryl;
R3 is selected from -
a) heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -SO2alkyl, -SO2NH(alkyl), -SO2NH2, -SO2NH(CF3), -SO2N(alkyl)2, -NHSO2(alkyl), -COR6, -CON(H)OH, -CONR5R5a, -N(R5)COR5a, and -NR5R5a,
b) aryl or aryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -SO2alkyl, -SO2NH(alkyl), -SO2NH2, -SO2NH(CF3), -SO2N(alkyl)2, -NHSO2(alkyl), -COR6, -CONR5R5a, -CO(NH)OH, -N(R5)COR5a, -NR5R5a, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,
c) heterocyclyl or heterocyclyl substituted with 1 to 4 substituents selected from oxo (=O) and substituted or unsubstituted alkyl, and
wherein, X is halogen and ring A is a heterocyclic ring containing heteroatom(s) selected from S, O, and N, which is optionally substituted with an oxo (=O) group;
R4 is selected from hydrogen, cycloalkyl, and substituted or unsubstituted alkyl;
R4a is selected from
a) hydrogen, alkyl, and cycloalkyl, and

b) alkyl substituted with 1 to 4 substituents independently selected from halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl;
R4b is selected from hydrogen and alkyl;
R5 and R5a are each independently selected from
a) hydrogen, alkyl, and cycloalkyl,
b) alkyl substituted with 'O-alkyl, 'NH2, and -CONH2,
c) heteroaryl, and
d) heterocyclyl substituted with alkyl; and
R6 is selected from alkyl, heterocyclyl, and cycloalkyl;
when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, -OR7, -C(=O)OH, -C(=O)O(alkyl), -NR8R8a, -NR8C(=O)R9, and 'C(=O)NR8R8a;
when the aryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, heteroaryl, -OR7, -NR8R8a, -NR8C(=O)R9, 'C(=O)R9, ' C(=O)NR8R8a, -SO2-alkyl, -C(=O)OH, -C(=O)O-alkyl, and haloalkyl;
when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR7, -NR8R8a, -NR7C(=O)R5, 'C(=O)R9, 'C(=O)NR8R8a, -SO2-alkyl, -C(=O)OH, and -C(=O)O-alkyl;
when the heterocycle group is substituted, it is substituted either on a ring carbon atom or on a ring hetero atom, and when it is substituted on a ring carbon atom, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, alkyl, cycloalkyl, perhaloalkyl, -OR7, C(=O)NR8R8a, -C(=O)OH, -C(=O)O-alkyl, -N(H)C(=O)(alkyl), -N(H)R8, and -N(alkyl)2; and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl,

aryl, heteroaryl, -SO2(alkyl), 'C(=O)R9, and C(=O)O(alkyl); when the heterocycle group is substituted on a ring sulfur, it is substituted with 1 or 2 oxo (=0) group(s);
R7 is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;
R8 and R8a are each independently selected from hydrogen, alkyl, and cycloalkyl; and
R9 is selected from alkyl and cycloalkyl.
In accordance with an embodiment of the invention, R1 is selected from hydrogen and substituted or unsubstituted alkyl.
In certain embodiments, R1 is selected from hydrogen, methyl, ethyl, and -CF3.
In any of the above embodiments, R2 is selected from
a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from halogen, cycloalkyl, substituted or unsubstituted heterocyclyl, -OR4, -NR5R5a, and substituted or unsubstituted aryl,
b) cycloalkyl or cycloalkyl substituted with substituted or unsubstituted alkyl,
c) cycloalkenyl,
d) substituted or unsubstituted aryl,
e) substituted or unsubstituted heteroaryl,
f) heterocyclyl or heterocyclyl substituted on ring carbon atom with 1 to 2 substituents independently selected from halogen, -OR4, and substituted or unsubstituted alkyl, and
g) -NRaRb, wherein Ra and Rb are independent selected from cycloalkyl and alkyl or alkyl substituted with 1 to 2 substituents independently selected from cycloalkyl, OR4, and substituted or unsubstituted aryl.
In certain embodiments, R2 is selected from


In any of the above embodiments, R3 is selected from

a) heteroaryl substituted with 1 to 3 substitutents selected from halogen, cyano, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl,
b) aryl substituted with 1 to 3 substituents selected from halogen, cyano, -OR4a, COOR4b, substituted or unsubstituted alkyl, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,
c) heterocyclyl substituted with 1 to 3 substituents selected from oxo (=0) and substituted or unsubstituted alkyl, and
wherein, X is chlorine and ring A is a heterocyclic ring containing N, which is optionally substituted with an oxo (=O) group.
In certain embodiments, R3 is selected from

In any of the above embodiments, R4 is selected from hydrogen and substituted or unsubstituted alkyl.
In any of the above embodiments, R4a is selected from alkyl or alkyl substituetd with 1 to 2 substituents independently selected from halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl.
In any of the above embodiments, R4b is alkyl.
In any of the above embodiments, R5 and R5a are each independently selected from alkyl.
Whenever a range of the number of atoms in a structure is indicated (e.g., a C1 to C20 alkyl etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used. Thus, for instance, the recitation of a range of 1-6 carbon atoms (e.g., C1 to C6), 2-6 carbon atoms (e.g., C2 to C6), 3-6 carbon atoms (e.g., C3to C6), as used with

respect to any chemical group (e.g., alkyl etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, and/or 6 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, as appropriate).
General terms used in formula can be defined as follows; however, the meaning stated should not be interpreted as limiting the scope of the term per se.
The term alkyl', as used herein, means a straight chain or branched hydrocarbon containing from 1 to 20 carbon atoms. Preferably, the alkyl chain may contain 1 to 10 carbon atoms. More preferably, alkyl chain may contain up to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
The term haloalkyl', as used herein means an alkyl group as defined hereinabove wherein at least one of the hydrogen atoms of the said alkyl group is substituted with halogen. The haloalkyl group is exemplified by chloromethyl, 1 -chloroethyl, and the like.
The term "perhaloalkyl", as used herein, means an alkyl group as defined hereinabove wherein all the hydrogen atoms of the said alkyl group are substituted with halogen. The perhaloalkyl group is exemplified by trifluoromethyl, pentafluoroethyl, and the like.
The term cycloalkyl' as used herein, means a monocyclic, bicyclic, or tricyclic non-aromatic ring system containing from 3 to 14 carbon atoms, preferably monocyclic cycloalkyl ring containing 3 to 6 carbon atoms. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Bicyclic ring systems include monocyclic ring system fused across a bond with another cyclic system which may be an alicyclic ring or an aromatic ring. Bicyclic rings also include spirocyclic systems wherein the second ring gets annulated on a single carbon atom. Bicyclic ring

systems are also exemplified by a bridged monocyclic ring system in which two
non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene
bridge. Representative examples of bicyclic ring systems include, but are not
limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane,
bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane,
bicyclo[3.3.2]decane, bicyclo[3.1.0]hexane, bicyclo[4.1.0]heptane,
bicyclo[3.2.0]heptanes, octahydro-1 H-indene, spiro[2.5]octane, spiro[4.5]decane,
spiro[bicyclo[4.1.0]heptane-2,1 '-cyclopentane], hexahydro-2'H-
spiro[cyclopropane-1,1'-pentalene]. Tricyclic ring systems are the systems wherein the bicyclic systems as described above are further annulated with third ring, which may be an alicyclic ring or aromatic ring. Tricyclic ring systems are also exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge. Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.03.7]nonane, and tricyclo[3.3.1.13.7]decane (adamantane).
The term cycloalkenyl' as used herein, means a cycloalkyl group as defined above containing at least one double bond.
The term aryl', as used herein, refers to a monovalent monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring system. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like. Aryl group also include partially saturated bicyclic and tricyclic aromatic hydrocarbons, e.g. tetrahydro-naphthalene. Aryl group also include bicyclic systems like 2,3-dihydro-indene-5-yl, and 2,3-dihydro-1-indenone-5-yl.
The term heteroaryl', as used herein, refers to a 5-14 membered monocyclic,
bicyclic, or tricyclic ring system having 1-4 ring heteroatoms selected from 0, N,
or S, and the remainder ring atoms being carbon (with appropriate hydrogen
atoms unless otherwise indicated), wherein at least one ring in the ring system
is aromatic. The term heteroaryl' as used herein, also include partially
saturated bicyclic and tricyclic aromatic ring system, e.g. 2,3-dihydro-
isobenzofuran-5-yl, 2,3-dihydro-1 -isobenzofuranone-5-yl, 2,3-dihydro-1 H-indol-
4-yl, 2,3-dihydro-1 H-indol-6-yl, and 2,3-dihydro-1-isoindolinone-5-yl.

Heteroaryl groups may be optionally substituted with one or more substituents.
In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may
be substituted by a substituent. Examples of heteroaryl groups include, but not
limited to, 1 H-1,2,3-triazolyl, 2H-1,2,3-triazolyl , pyridyl, 1-oxo-pyridyl, furanyl,
thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl,
quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,
triazolyl, thiadiazolyl, isoquinolinyl, benzoxazolyl, benzofuranyl, indolizinyl,
imidazopyridyl, imidazolyl, tetrazolyl, benzimidazolyl, benzothiazolyl,
benzothiadiazolyl, benzoxadiazolyl, indolyl, azaindolyl, imidazopyridyl,
quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4]pyrimidinyl, and
benzo(b)thienyl, 2,3-thiadiazolyl, 1 H-pyrazolo[5,1-c]-1,2,4-triazolyl, pyrrolo[3,4-
d]-1,2,3-triazolyl, cyclopentatriazolyl, 3H-pyrrolo[3,4-c] isoxazolyl, 2,3-dihydro-
benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, 2,3-d i hydro-
benzofuran-5-yI, 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro-benzofuran-6-yl,
2,3-dihydro-benzofuran-6-yl, 2,3-dihydro-isobenzofuran-5-yl, 2,3-dihydro-1-
isobenzofuranone-5-yl, 2,3-dihydro-1 H-indol-5-yl, 2,3-dihydro-1 H-indol-4-yl,
2,3-dihydro-1 H-indol-6-yl, 2,3-dihydro-1 H-indol-7-yl, 2,3-dihydro-1-
isoindolinone-5-yl, benzo[1,3]dioxol-4-yl, benzo[1,3]dioxol-5-yl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 2,3-dihydrobenzothien-4-yl, 2-oxoindolin-5-yl and the like.
The term heterocycle' or "heterocyclic' or heterocyclyl' as used herein, means a cycloalkyl' or cycloalkenyl' group wherein one or more of the carbon atoms are replaced by heteroatoms/groups selected from N, S, SO2 and O. The heterocycle may be connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1.1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl.

Representative examples of bicyclic heterocycle include, but are not limited to,
1,2,3,4-tetrahydroisoquinolin-2-yl, 1,2,3,4-tetrahydroquinol in-1-yl, 1,3-
benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-1-
benzofuranyl, 2,3-dihydro-1-benzothienyl, 2,3-dihydro-1 H-indolyl, and 1,2,3,4-
tetrahydroquinolinyl. The term heterocycle also includes bridged and spiro
heterocyclic systems such as azabicyclo[3.2.1]octane, azabicyclo[3.3.1]nonane,
8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 6-oxa-
3-azabicyclo[3.1.1]heptan-3-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3-
azabicyclo[3.2.1]octan-3-yl, 3-azabicyclo[3.1.0]hexan-3-yl, 6-azaspiro[2.5]octan-6-yl, 5-azaspiro[2.5]octan-5-yl, 4-azaspiro[2.4]heptan-4-yl, and the like.
The "halogen' means fluorine, chlorine, bromine, or iodine. The halogen group is exemplified by fluorine, chlorine, and bromine.
The term oxo' means a divalent oxygen (=O) attached to the parent group. For example, oxo attached to carbon forms a carbonyl, oxo substituted on cyclohexane forms a cyclohexanone, and the like.
The term annulated' means the ring system under consideration is either annulated with another ring at a carbon atom of the cyclic system or across a bond of the cyclic system as in the case of fused or spiro ring systems.
The term bridged' means the ring system under consideration contain an alkylene bridge having 1 to 4 methylene units joining two non-adjacent ring atoms.
A compound, its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, its solvate, its combination with suitable medicament, its pharmaceutical composition thereof as described hereinabove wherein the compound of general formula (I), is selected from the group consisting of:
1. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo [5,4-
b]pyridin-6-yl)urea (Compound 1);
2. 1-(3-Chloro-4-methoxyphenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 2);

3. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-
(trifluoromethyl)pyridin-4-yl)urea (Compound 3);
4. 1-(5-Chloro-6-ethoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 4);
5. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1 -methyl-2-oxo-5-
(trifluoromethyl)-1,2-dihydropyridin-3-yl)urea (Compound 5);
6. 1-(5-Chloro-6-isopropoxypyridin-3-yl)-3-(7-cyclopropyl-2 methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 6);
7. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-
(trifluoromethyl)pyridin-3-yl)urea (Compound 7);
8. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-methoxy-5-
(trifluoromethyl)pyridin-3-yl)urea (Compound 8);
9. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 9);
1 0. 1 -(5-Cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 10);
11. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-
(difluoromethyl)pyridin-3-yl)urea (Compound 11);
1 2. 1 -(2-Cyanopyridin-4-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 12);
1 3. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2,7-di methyl thiazolo[5,4-b] pyridin-6-yl)urea (Compound 13);
14. 1 -(3-Chloro-4-methoxyphenyl)-3-(2,7- dimethylthiazolo[5,4-b]pyridin-6-
yl)urea (Compound 14);
1 5. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-fluoro-2-methoxyphenyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 15);

1 6. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-fluoropyridin-3-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 16);
1 7. 1 -(3-Chloro-4-methoxyphenyl)-3-(7-(2-fluoropyridin-3-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 17);
1 8. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-fluoropyridin-4-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 18);
19. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-cyclopropyl-
2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 19);
20. 1-(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 20);
21. 1 -(5-Chloro-2-oxoindolin-7-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 21);
22. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(2H-
1,2,3-triazol-2-yl)pyridin-3-yl)urea (Compound 22);
23. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(1,1 -
dioxidoisothiazolidin-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 23);
24. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)urea (Compound 24);
25. 1-(3-Chloro-4-methoxyphenyl)-3-(7-ethyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 25);
26. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-ethyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 26);
27. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4,4-difluoropiperidin-
1 -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 27);
28. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-
morpholinothiazolo[5,4-b]pyridin-6-yl)urea (Compound 28);

29. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4-methoxypiperidin-
1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 29);
30. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-methoxypiperidin-1-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 30);
31. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-
ethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 31);
32. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 32);
33. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 33);
34. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1,2-dimethoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 34);
35. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
cyclopropylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 35);
36. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropylthiazolo[5,4-b]pyridin-6-
yl)urea (Compound 36);
37. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(4-
methylpiperidin-1-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 37);
38. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2,6-dimethylmorpholino)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 38);
39. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2,6-
dimethylmorpholino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 39);
40. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(piperidin-1-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 40);
41. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((cyclopropylmethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 41);

42. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
((cyclopropylmethyl)(methyl)annino)-2-nnethylthiazolo[5,4-b]pyriclin-6-yl)urea
(Compound 42);
43. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2,3-
dimethoxypropyl)(methyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 43);
44. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2-
methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 44);
45. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxyethyl)(methyl)amino)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 45);
46. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1,3-
di met hoxypropan-2-yl)(methyl)amino)-2-methyl thiazolo[5,4-b]pyridin-6-yl)urea
(Compound 46);
47. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2-(4-fluorophenyl)-2-
methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 47);
48. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(2-
methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 48);
49. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclopropyl(2-
methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 49);
50. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3-
(methoxymethyl)piperidin-l -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 50);
51. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-(methoxymethyl)piperidin-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 51);
52. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3-methoxypiperidin-1 -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 52);

53. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1-methoxypropan-2-
yl)(nnethyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 53);
54. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((1-methoxypropan-2-
yl)(methyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 54);
55. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxypropyl)(methyl)amino)-
2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 55);
56. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2,2-
dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 56);
57. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-
2,2-dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 57);
58. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3,6-dihydro-2H-pyran-4-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 58);
59. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclohex-1-en-1-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 59);
60. 1-(5-Chloro-6-cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 60);
61. 1-(5-Chloro-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 61);
62. 1-(5-Cyano-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 62);
63. 1-(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 63);
64. 1 -(3-C hloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1 -
(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 64);
65. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-(methoxymethyl)cyclopropyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 65);

66. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1,4-oxazepan-4-
yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 66);
67. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(1,4-
oxazepan-4-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 67);
68. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(cyclopropyl(2-methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 68);
69. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclopropyl(2-methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 69);
70. 1 -(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(cyclopropyl(2-
methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 70);
71. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-hydroxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 71);
72. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-fluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 72);
73. 1-(5-Chloro-6-(2-(1-methyl piperidin-4-yl)ethoxy)pyridin-3-yl)-3-(7-
cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 73);
74. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(dimethylamino)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 74);
75. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 75);
76. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 76);
77. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-(pyrrolidin-1-
yl)ethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 77);

78. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-
2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 78);
79. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2-
methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 79);
80. 1 -(7-(1 -Methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-
methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea
(Compound 80);
81. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
81);
82. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(methoxy(phenyl)methyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 82);
83. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
83);
84. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
(methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
84);
85. 1 -(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-((4-
fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 85);
86. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-((4-
fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 86);
87. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-((4-
fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 87);
88. 1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 88);

89. 1-(5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 89);
90. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 90);
91. 1-(5-Chloro-2-methoxy-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 91);
92. 1-(5-Chloro-6-methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 92);
93. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
cyclopropyl-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 93);
94. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-cyclopropyl-1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 94);
95. 1 -(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-
(2,2,2-trifluoro-1 -methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 95);
96. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2-
methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 96);
97. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(2-
methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 97);
98. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(2-methoxypropan-2-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 98);
99. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-
(cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
99);
100. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
100);

101. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
(methoxymethyl)cyclopropyl)-2-nnethylthiazolo[5,4-b]pyriclin-6-yl)urea
(Compound 101);
102. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
(methoxymethyl)cyclopropyl)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 102);
103. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-
(trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 103);
104. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-
(trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 104);
105. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
(hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 105);
1 06. 1 -(3-C hloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1 -
(hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 1 06);
1 07. 1 -(3-C hloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1 -
(fluoromethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 107);
108. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
((dimethylamino)methyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 108);
109. 1-(5-chloro-2,4-dimethoxyphenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 109);
110. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(dimethylamino)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 110);
111. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(pyrrolidin-1-
yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 111);

112. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-nnorpholinothiazolo[5,4-
b]pyridin-6-yl)urea (Compound 112);
113. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4,4-difluoropiperidin-1-yl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 113);
114. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-
(difluoromethyl)pyridin-4-yl)urea (Compound 114);
115. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 115);
116. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-ethylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 116);
117. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1-
methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 117);
118. 1-(3-chloro-4-methoxyphenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 118);
119. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 119);
120. 1-(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 120);
121. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-(2-methoxyethoxy)ethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 121);
122. 1-(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 122);
123. 1-(5-Chloro-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 123);
1 24. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 124);

125. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxy-2-
methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 125);
126. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 126);
127. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-methoxypropyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 127);
128. 1-(5-Chloro-2-methoxyphenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 128);
129. 1-(5-Cyanopyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 129);
1 30. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-
(trifluoromethyl)pyridin-4-yl)urea (Compound 130);
131. 1-(5-Chloro-2-methoxy-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 131);
132. 1-(5-Chloro-2-methoxy-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 132);
1 33. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1 -methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)urea (Compound 133);
134. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropan-2-yl)-
2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 134);
135. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydrofuran-2-
yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 135);
136. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-
(tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 136);
137. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-
(tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 137);

138. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 138);
1 39. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 139);
140. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-
(tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 140);
141. 1 -(6-(1 H-1,2,3-Triazol-1 -yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 141);
142. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 142);
143. 1 -(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1 -
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 143);
144. 1 -(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-
(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 144);
145. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxypropyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 145);
146. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 146);
147. 1 -(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1 -
methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 147);
148. 1-(5-Chloro-6-(5-methyloxazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 148);
149. 1-(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 149);
150. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 150);

151. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(cyclopropyl(methoxy)methyl)-2-nnethylthiazolo[5,4-b]pyriclin-6-yl)urea (Compound 151);
1 52. Methyl 3-chloro-5-(3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)ureido)benzoate (Compound 1 52);
153. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-
(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 1 53);
154. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 1 54);
155. 1-(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-
(2-methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea
(Compound 1 55);
156. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 1 56);
157. 1-(7-(sec-Butyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-chloro-6-(2H-
1,2,3-triazol-2-yl)pyridin-3-yl)urea (Compound 157);
158. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 158);
159. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 159);
160. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 160);
161. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-ethoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 161);

162. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 162);
163. 1-(3-Chloro-4-methoxyphenyl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-
b]pyridin-6-yl)urea (Compound 163);
164. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 164);
165. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 165);
166. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 166);
167. 1-(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 167);
168. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 168);
169. 1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 169);
170. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(3,5-dichloro-4-
(1H-1,2,3-triazol-1-yl)phenyl)urea (Compound 170);
171. 1-(3-Cyano-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 171);
172. 1-(3-Cyano-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 172);
173. 1-(3-Chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 173);
174. 1-(3-Chloro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 174);

1 75. 1 -(5-Bromo-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 175);
176. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(methoxymethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 176);
1 77. 1 -(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-(1 - methyl eye lopropyl)thiazolo[5,4- b]pyridin-6-yl)urea (Compound 177);
178. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-
(1 - methyl eye lopropyl)thiazolo[5,4- b]pyridin-6-yl)urea (Compound 178);
179. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-
methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 179);
180. 1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-
methyl-7-(1 -methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 180);
181. 1-(5-Chloro-6-(1H-pyrazol-1-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 181);
182. 1-(3-Chloro-4-(1H-pyrazol-1-yl)phenyl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 182);
183. 1-(3-Chloro-4-(3-(methoxymethyl)-5-methyl-1H-pyrazol-1-yl)phenyl)-3-(7-
cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 183);
184. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-
2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 184);
185. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-(2-
methoxyethoxy)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 185);
186. 1-(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-isopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 186);
1 87. 1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 187);

188. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-isopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 188);
189. 1-(5-Chlorothiophen-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 189);
190. 1-(5-Chlorothiophen-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 190);
191. 1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-isopropyl-
2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 191);
1 92. 1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 192);
1 93. 1 -(3-Chloro-4-(difluoromethoxy)phenyl)-3-(7-cyclopropyl-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 193);
194. 1-(5-Chloro-6-(1-methyl-1H-pyrazol-5-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 194);
1 95. 1 -(5-C hloro-2-(2-(dimethylamino)ethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 195);
196. 1-(5-Chloro-6-(1H-pyrazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 196);
197. 1-(5-Chloro-6-(isoxazol-4-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 197);
198. 1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 198);
199. 1-(3-Chloro-4-(pyrazin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 199);
200. 1-(5-Cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 200);

201. 1-(3-Chloro-4-(1H-pyrazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 201);
202. 1-(3-Chloro-4-(pyrimidin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 202);
203. 1-(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 203);
204. 1-(3-Chloro-4-(oxazol-5-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 204);
205. 1-(5-(Difluoromethyl)-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 205);
206. 1-(5-(Difluoromethyl)-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 206);
207. 1-(3-(Difluoromethyl)-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 207);
208. 1-(3-Cyano-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 208);
209. 1-(5-Chloro-2-methoxy-6-(1H-pyrazol-1-yl)pyridin-3-yl)-3-(7-(1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 209);
210. 1-(4-(1H-Pyrazol-1-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 210);
211. 1-(3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 211);
212. 1-(5-Fluoro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 212);
213. 1-(6-(1H-Pyrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 21 3);

214. 1-(4-(Difluoromethoxy)-3-(trifluoromethyl)phenyl)-3-(7-(1-nnethoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 214);
215. 1-(3-Chloro-4-(1H-imidazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-
methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 215);
216. 1-(3-Chloro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-3-(7-(1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 21 6);
217. 1-(3-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)phenyl)-3-(7-(1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 21 7);
218. 1-(5-Chloro-6-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 218);
219. 1-(5-Chloro-2-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 219);
220. 1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-
(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 220);
221. 1-(2-Ethoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 221);
222. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-
(trifluoromethyl)pyridin-3-yl)urea (Compound 222);
223. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
(hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 223);
224. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-
(cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 224);
225. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
(cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 225);

226. 1-(7-(Cyclopropyl(methoxy)methyl)-2-nnethylthiazolo[5,4-b]pyriclin-6-yl)-3-
(2-ethoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea
(Compound 226);
227. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
(dimethylannino)propyl)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
227);
228. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
(cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 228);
229. 1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(3,3-
difluoroazetidin-1-yl)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (compound
229);
230. 1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
(dimethylamino)-2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 230);
231. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(dimethylamino)-
2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 231);
232. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-ethyl-7-(1-
methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 232);
233. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-ethyl-7-(1-
methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 233);
234. 1 -(6-((S)-2-Aminopropoxy)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 -
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea hydrochloride
(Compound 234);
235. 1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(((R)-1-
methoxypropan-2-yl)(methyl)amino)-5-(trifluoromethyl)pyridin-3-yl)urea
(Compound 235);
236. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(thiazol-2-
ylamino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 236);

237. N-(5-(3-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)ureido)-3-
(trifluoromethyl)pyridin-2-yl)acetamide (Compound 237);
238. 1-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-
(methoxymethyl)-5-(trifluoronnethyl)pyridin-3-yl)urea (Compound 238);
239. 1-(6-(1H-Tetrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 239); and
240. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2-
cyclopropyl-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea
(Compound 240).
According to a feature of the present invention, the compounds of general formula (I) where all the symbols are as defined earlier, can be prepared by methods illustrated in the schemes and examples provided herein below. However, the disclosure should not be construed to limit the scope of the invention arriving at compound of formula (I) as disclosed hereinabove.
Scheme 1

The compounds of formula (I), wherein R1, R2, R3 are as defined herein above, can be prepared as depicted in Scheme 1. The compounds of formula (3) can be

prepared by the reaction of compounds of formula (1) with thioamides of formula (2) followed by cyclisation in sulfolane. The compounds of formula (3) can be reduced to the corresponding amines of formula (4) with reducing agents known in the art. Although not limited, such reducing agents include hydrogenation with palladium on carbon, metal reductions like iron, tin or tin chloride and the like. Such reduction of the compounds of formula (3) can be carried out in one or more solvents, e.g., ethers such as THF, 1,4-dioxane and the like; alcohols such as methanol, ethanol and the like; under acidic conditions involving ammonium chloride, acetic acid, hydrochloric acid and the like or mixture(s) thereof.
The compounds of formula (4) can be converted to the compounds of formula (5) via halogenation by methods known in the art. Preferably, compounds of formula (4) are treated with N-halosuccinamides such as NBS, NIS and the like; or with bromine or any other halogenating agent known in the art. Halogenation reactions can be carried out in one or more solvents, e.g., ether solvents such as THF and the like; chlorinated solvents such as DCM, chloroform and the like; acids such as acetic acid and the like; amides such as DMF and the like or mixture(s) thereof.
The compounds of formula (7) can be prepared by the reaction of compounds of formula (5) with boronic acid/stannane derivatives of formula (6). The same transformation may also be carried out by other suitable coupling methods known in the art. The above reaction can be mediated by a suitable catalyst known in the art such as, e.g., Pd(PPh3)2CI2, Pd2dba3, Pd(PPh3)4, Pd(OAc)2 or mixture(s) thereof; a suitable ligand known in the art such as BINAP, xantphos, triphenylphosphine or mixture(s) thereof; in the presence of a suitable base, preferably inorganic bases such as alkali metal carbonates, e.g., sodium carbonate and cesium carbonate, and phosphates like potassium phosphate, or mixture(s) thereof. As also known from the art, such reactions are effected in solvents, e.g., ethers such as tetrahydrofuran, dioxane, and the like; hydrocarbons, e.g., toluene; amides such as DMA, DMF and the like; sulfoxides, e.g., dimethylsulfoxide; halogenated hydrocarbons, e.g., DCM or mixture(s) thereof.

The compounds of formula (8) can be prepared from the corresponding amines by reacting with phenyl chloroformate by following methods known in the art.
The compounds of formula (7) can be subsequently converted to the compounds of the formula (I) by reacting with carbamates of the formula (8). The same transformation may also be carried out by other methods known in the art. The above reaction can be carried out in the presence of an organic base such as triethyl amine, ethyldiisopropyl amine, pyridine and the like. Also known from the art, such reactions are effected in solvents like ethers such as THF, dioxane and the like; hydrocarbons such as toluene and the like; halogenated hydrocarbons like DCM; sulfoxides like DMSO or mixture(s) thereof.
Compounds of formula (7) can also be transformed into the compounds of formula (I) by treating with chloroformates such as phenyl chloroformate of formula (9) to provide carbamates of the formula (10) by following methods known in the art, followed by treatment with amines of formula (11) by following the methods known in the art or as described for the conversion of compounds of formula (7) to (I). Compounds of formula (11) are either commercially available or can be prepared by following the methods known in the art or as described in the synthetic schemes herein.
Alternatively, compounds of formula (7) can be transformed to compounds of the present invention of formula (I) by treating with amine of formula (11) by using coupling reagents, although not limited to, such as triphosgene, carbonyl diimidazole, dicyclohexyl carbodiimide, diethyl carbonate and the like; in one or more solvents like DCM, THF, toluene, DMF, DMA or mixture(s) thereof.
Scheme 2


Alternatively, the compounds of the formula (I) can also be prepared by following the methods as described in Scheme 2. Nitration of the compounds of formula (12) with nitrating agents such as nitric acid, potassium nitrate and the like in acids such as sulfuric acid, trifluoroacetic acid, acetic acid and the like; anhydrides like acetic anhydride, trifluoroacetic anhydride and the like; or mixture(s) thereof provides the compounds of formula (13) or by the methods known in the art. Reaction of the compounds of formula (13) with thioamides of formula (2) followed by cyclization in sulfolane by following the methods described in the art provides the compounds of formula (14). Treatment of the compounds of formula (14) under Sandmeyer reaction conditions can provide the compounds of formula (15). The above reaction can be carried out with nitrites such as sodium nitrite, tri-butyl nitrite and the like; copper halides like copper chloride, copper bromide, copper iodide and the like. The solvents used for the above transformation are, e.g., acetonitrile and the transformation is carried out in an acidic media, e.g., hydrochloric acid.
Compounds of formula (1 5) can be converted to the compounds of formula (16) by following ethods known in the art or as described in the synthetic Schemel for the transformation of compounds of formulas (5) to (7).
Reduction of the nitro group of the compounds of formula (16) to produce the compounds of formula (7) can be carried out either using hydrogenation over Palladium on carbon, or metals like iron, tin or tin chloride in acidic media, e.g., hydrochloric acid or in the presence of protic solvents like methanol, ethanol or mixture(s) thereof. The compounds of formula (7) can be converted to the

compounds of the present invention of formula (I) by following methods as described in general Schemel
Scheme-3

In another embodiment, the compounds of the present invention of the formula (I) can be prepared as described in Scheme-3. Compounds of formula (15) can be reacted with amines of formula (17) to provide the compounds of formula (18). The above reaction can be carried out in the presence of a suitable base such as a metal hydride, e.g., sodium hydride and the like; an organic base such as triethyl amine, ethyldiisopropyl amine, and the like; or an inorganic base such as sodium carbonate, potassium carbonate, cesium carbonate, and the like. Such amination reactions can be carried out in one or more solvents such as ethers, e.g., THF, dioxane, and the like; alcohols such as methanol, ethanol, isopropanol and the like; hydrocarbons such as toluene and the like; or amides such as DMF, DMA and the like or mixture(s) thereof.
Compounds of formula (18) can be reduced to the amines of formula (19) with a reducing agent known in the art. Although not limited, such reducing agents include hydrogenation with palladium on carbon, metal reductions like iron, tin or tin chloride and the like. Reduction of the compounds of formula (18) can be carried out in one or more solvents like ethers such as THF, dioxane and the like; alcohols such as methanol, ethanol and the like; acids such as acetic acid and the like; or mixture(s) thereof.
Compounds of formula (19) can be converted to the compounds of the present invention of the formula (I) by reacting with the compounds of the formula (8) by

following the methods described in Scheme-1 for the reaction of compounds of formula (7) to (I). Alternatively, the same transformation can also be carried out by reacting with compounds of formula (20). The coupling agents used for such transformation are DPPA, sodium azide, or any other agents known in the art. The bases used for the said reaction are organic bases such as triethyl amine, diisopropylethyl amine and the like. The coupling reaction can be carried out in solvents like ethers such as dioxane, THF and the like; hydrocarbons like toluene and the like; amides such as DMF, DMA and the like; nitriles such as acetonitrile and the like or mixture(s) thereof. Compounds of formula (19) can be converted to the compounds of the present invention of formula (I) by treating with amines of formula (11) by following methods known in the art or as described for the conversion of compounds of formula (7) to (I), depicted in Scheme 1.

Scheme 4 depicts a method of preparation of the compounds of formula (I) starting from the amine derivatives of the formula (21), which undergoes Michael substitution reaction with dialkyl 2-(alkoxymethylene)malonate (22) to afford the compounds of formula (23). Such reactions can be carried out either neat or in alcoholic solvents such as methanol, ethanol and the like; or by methods known in the art. Treatment of the compounds of formula (23) with halogenating reagents such as POCI3 or POBr3 causes ring cyclisation followed by halogenation in one pot and leads to the compounds of formula (24). Such reactions can be carried out either neat or in presence of hydrocarbons such as toluene, xylene and the like or mixture(s) thereof.

Compounds of formula (24) can be converted to the compounds of formula (25) by reacting with boronic acid derivatives of the formula (6) by following the methods known in the art or as described for the preparation of compounds of the formula (7) in Scheme-1. Hydrolysis of the compounds of the formula (25) by using a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; in a solvent such as THF, water, methanol, ethanol or a mixture(s) thereof to afford the corresponding acids of the formula (26).
Carboxylic acids of formula (26) can be transformed by treatment with DPPA and a tertiary amine base to generate acyl azides which undergoes rearrangement (Curtius rearrangement) upon heating to form intermediate isocyanates which can be intercepted by appropriate amines of formula (11) to afford urea derivatives of formula (I).


In another embodiment, as described in Scheme 5, compounds of the formula (24) can be converted to the compounds of the formula (28) by reacting with stannane derivatives of the formula (27) by following methods known in the art. The same transformation may also be carried out by other suitable coupling methods known in the art. The above reaction can be mediated by a suitable catalyst known in the art such as Pd(PPh3)2CI2, Pd2dba3, Pd(PPh3)4, Pd(OAc)2 or mixture(s) thereof; a suitable ligand known in the art such as BINAP, xanthophos, triphenylphosphine or mixture(s) thereof. As also known from the art, such reactions are effected in the solvents like ethers such as tetrahydrofuran, 1,4-dioxane, and the like; hydrocarbons like toluene; amides such as DMA, DMF and the like or mixture(s) thereof.
Hydrogenation of the compounds of the formula (28) can provide compounds of the formula (29). The said reaction can be carried out although not limited, in presence of a catalyst such as palladium on carbon, palladium hydroxide and the like in presence of hydrogen atmosphere; in one or more solvents like ethers such as THF, 1,4-dioxane and the like; alcohols such as methanol, ethanol and the like; or mixture(s) thereof.
Hydrolysis of the compounds of the formula (29) using the base(s) such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; in solvents like THF, water, methanol, ethanol or a mixture(s) thereof to afford the corresponding acids of the formula (30).
Carboxylic acids of formula (30) can be transformed by treatment with DPPA and a tertiary amine base to acyl azides which undergoes rearrangement (Curtius rearrangement) upon heating to form intermediate isocyanates which can be intercepted by appropriate amines of formula (11) to afford urea derivatives of formula (I).
Compounds of the formula (28) can be subjected to acidic hydrolysis by using acids such as hydrochloric acid and the like; in one or more solvents like 1,4-dioxane, THF or a mixture(s) thereof to provide compounds of the formula (31).
Reduction of the ketone compounds of the formula (31) undergoes in situ lactonisation to provide compounds of the formula (32) by treating with a

reducing agent, although not limited, such as sodium borohydride, nickel boride, cobalt boride, diisobutyl aluminium hydride, and the like, in one or more solvents, for example, methanol, ethanol, THF or mixture(s) thereof.
Compounds of the formula (33) can be prepared by hydrolysis of the compounds of the formula (32). Such transformation is carried out by using the base(s) such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; in solvents like THF, water, methanol, ethanol or a mixture(s) thereof.
Alkylation of the compounds of the formula (33) with alkyl halides such as methyl iodide, ethyl iodide, propyl bromide; by using a basesuch as sodium hydride, lithium hexamethyldisilazine, cesium carbonate, potassium carbonate, sodium carbonate and the like, in one or more solvents such as DMF, DMA, THF, toluene or mixture(s) thereof to provide compounds of the formula (34).
Upon hydrolysis, compounds of the formula (34) can be converted to the compounds of the formula (35) by following methods known in the art or as described for compounds of formula (29).
Compounds of the formula (33) can also be converted into compounds of formula (35) by treating with alkyl halides such as methyl iodide, ethyl iodide, propyl bromide; by using bases such as sodium hydride, potassium tert-butoxide, sodium tert-butoxide and the like; in one or more solvents such as DMF, DMA, THF or mixture(s) thereof.
Compounds of formula (35) can be converted to the compounds of the present invention of the formula (I) by reacting with amine of formula (11) by following the methods described for compounds of formula (30).
Scheme-6

CLAIMS
1. A compound of the general formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof,

wherein,
R1 is selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, and cycloalkyl;
R2 is selected from -
a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted heterocyclyl, -OR4, -C(=O)OH, -SO2(alkyl), -C(=O)O(alkyl), -NR5R5a, -NR5C(=O)R6 'C(=O)R6, and 'C(=O)NR5R5a,-
b) cycloalkyl or cycloalkyl substituted with 1 to 4 substituents independently selected from halogen, cyano, substituted or unsubstituted alkyl, -OR4, -C(=O)OH,-C(=O)O(alkyl), 'C(=O)R6 and 'C(=O)NR5R5a,
c) cycloalkenyl,
d) cyano,
e) substituted or unsubstituted aryl,
f) substituted or unsubstituted heteroaryl,
g) heterocyclyl or heterocyclyl substituted on either ring carbon atom or a ring
nitrogen atom and when it is substituted on ring carbon atom it is substituted
with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano,

substituted or unsubstituted alkyl, cycloalkyl, -OR4, -C(=O)OH, -C(=O)O-alkyl, -C(=O)NR5N5a, -N(H)C(=O)(alkyl), -N(H)Rs, and -N(alkyl)2, and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -SO2(alkyl), 'C(=O)R6, C(=O)O(alkyl), -C(=O)N(H)R5, and -C(=O)N(alkyl)R5, and
h) -NRaRb, wherein, Ra and Rb are independent selected from hydrogen, cycloalkyl, and alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cycloalkyl, -OR4, and substituted or unsubstituted aryl;
R3 is selected from -
a) heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -S02alkyl, -S02NH(alkyl), -S02NH2, -SO2NH(CF3), -SO2N(alkyl)2, -NHSO2(alkyl), -COR6 -CON(H)OH, -CONR5R5a, . N(R5)COR5a, and -NR5R5a,
b) aryl or aryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -SO2alkyl, -SO2NH(alkyl), -SO2NH2, -SO2NH(CF3), -SO2N(alkyl)2, -NHSO2(alkyl), -COR6 -CONR5R5a, -CO(NH)OH, -N(R5)COR5a, -NR5R5a, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,
c) heterocyclyl or heterocyclyl substituted with 1 to 4 substituents selected from oxo (=O) and substituted or unsubstituted alkyl, and

d) wherein, X is halogen and ring A is a heterocyclic ring
containing heteroatom(s) selected from S, O, and N, which is optionally substituted with an oxo (=O) group;
R4 is selected from hydrogen, cycloalkyl, and substituted or unsubstituted alkyl;
R4a is selected from
a) hydrogen, alkyl, and cycloalkyl, and
b) alkyl substituted with 1 to 4 substituents independently selected from
halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl;
R4b is selected from hydrogen and alkyl;
R5 and R5a are each independently selected from
a) hydrogen, alkyl, and cycloalkyl,
b) alkyl substituted with 'O-alkyl, 'NH2, and -CONH2,
c) heteroaryl, and
d) heterocyclyl substituted with alkyl; and
R6 is selected from alkyl, heterocyclyl, and cycloalkyl;
when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, -OR7, -C(=O)OH, -C(=O)O(alkyl), -NR8R8a, -NR8C(=O)R9, and 'C(=O)NR8R8a;
when the aryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, heteroaryl, -OR7, -NR8R8a, -NR8C(=O)R9, 'C(=O)R9, ' C(=O)NR8R8a, -SO2-alkyl, -C(=O)OH, -C(=O)O-alkyl, and haloalkyl;

when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR7, -NR8R8a, -NR7C(=O)R9, 'C(=O)R9, 'C(=O)NR8R8a, -SO2-alkyl, -C(=O)OH, and -C(=O)O-alkyl;
when the heterocycle group is substituted, it is substituted either on a ring carbon atom or on a ring hetero atom, and when it is substituted on a ring carbon atom, it is substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, alkyl, cycloalkyl, perhaloalkyl, -OR7, C(=O)NR8R8a, -C(=O)OH, -C(=O)O-alkyl, -N(H)C(=O)(alkyl), -N(H)R8, and -N(alkyl)2; and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -SO2(alkyl), 'C(=O)R9, and C(=O)O(alkyl); when the heterocycle group is substituted on a ring sulfur, it is substituted with 1 or 2 oxo (=O) group(s);
R7 is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;
R8 and R8a are each independently selected from hydrogen, alkyl, and cycloalkyl; and
R9 is selected from alkyl and cycloalkyl.
2. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R1 is selected from hydrogen and substituted or unsubstituted alkyl.
3. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or 2, wherein R1 is selected from hydrogen, methyl, ethyl, and -CF3.
4. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, wherein R2 is selected from

a) alkyl or alkyl substituted with 1 to 4 substituents independently selected
from halogen, cycloalkyl, substituted or unsubstituted heterocyclyl, -OR4, -
NR5R5a, and substituted or unsubstituted aryl,
b) cycloalkyl or cycloalkyl substituted with substituted or unsubstituted alkyl,
c) cycloalkenyl,
d) substituted or unsubstituted aryl,
e) substituted or unsubstituted heteroaryl,

f) heterocyclyl or heterocyclyl substituted on ring carbon atom with 1 to 2 substituents independently selected from halogen, -OR4, and substituted or unsubstituted alkyl, and
g) -NRaRb, wherein Ra and Rb are independent selected from cycloalkyl and alkyl or alkyl substituted with 1 to 2 substituents independently selected from cycloalkyl, OR4, and substituted or unsubstituted aryl.
5. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, wherein R2 is selected from



6. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5, wherein R3 is selected from
a) heteroaryl substituted with 1 to 3 substitutents selected from halogen, cyano, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl,

b) aryl substituted with 1 to 3 substituents selected from halogen, cyano, -OR4a, COOR4b, substituted or unsubstituted alkyl, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,
c) heterocyclyl substituted with 1 to 3 substituents selected from oxo (=0) and substituted or unsubstituted alkyl, and
d) wherein, X is chlorine and ring A is heterocyclic ring containing N, which is optionally substituted with an oxo (=0) group.
7. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 6, wherein R3 is selected from

8. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7, wherein R4 is selected from hydrogen and substituted or unsubstituted alkyl.
9. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, wherein R4a is selected from alkyl or alkyl substituted with 1 to 2 substituents independently selected from halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl.

10. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 9, wherein R4b is alkyl.
11. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt

thereof, as claimed in any one of claims 1 to 10, wherein R5 and R5a are each independently selected from alkyl.
12. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 11, wherein R1 is selected from hydrogen and substituted or unsubstituted alkyl;
R2 is selected from
a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from halogen, cycloalkyl, heterocyclyl, -OR4, -NR5R5a, and substituted or unsubstituted aryl,
b) cycloalkyl or cycloalkyl substituted with substituted or unsubstituted alkyl,
c) cycloalkenyl,
d) substituted or unsubstituted aryl,
e) substituted or unsubstituted heteroaryl,
f) heterocyclyl or heterocyclyl substituted on ring carbon atom with 1 to 2 substituents independently selected from halogen, -OR4, and substituted or unsubstituted alkyl, and
g) -NRaRb, wherein Ra and Rb are independent selected from cycloalkyl and alkyl or alkyl substituted with 1 to 2 substituents independently selected from cycloalkyl, OR4, and substituted or unsubstituted aryl; and
R3 is selected from
a) heteroaryl substituted with 1 to 3 substitutents selected from halogen, cyano, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl,
b) aryl substituted with 1 to 3 substituents selected from halogen, cyano, -OR4a, COOR4b, substituted or unsubstituted alkyl, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,

c) heterocyclyl substituted with 1 to 3 substituents selected from oxo (=0) and
substituted or unsubstituted alkyl, and
d) wherein, X is chlorine and ring A is heterocyclic ring containing N, which is optionally substituted with an oxo (=0) group.
13. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 12, wherein:
R1 is selected from hydrogen, methyl, ethyl, and -CF3;
R2 is selected from

14. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, wherein the compound is selected from:
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo [5,4-
b]pyridin-6-yl)urea (Compound 1);
1 -(3-Chloro-4-methoxyphenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 2);
1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-(trifluoromethyl)pyridin-4-yl)urea (Compound 3);
1-(5-Chloro-6-ethoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 4);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)urea (Compound 5);
1 -(5-Chloro-6-isopropoxypyridin-3-yl)-3-(7-cyclopropyl-2 methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 6);
1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-(trifluoromethyl)pyridin-3-yl)urea (Compound 7);
1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 8);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 9);
1 -(5-Cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 10);
1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-(difluoromethyl)pyridin-3-yl)urea (Compound 11);
1 -(2-Cyanopyridin-4-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 12);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2,7-dimethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 13);
1 -(3-Chloro-4-methoxyphenyl)-3-(2,7- dimethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 14);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-fluoro-2-methoxyphenyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 15);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-fluoropyridin-3-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 16);
1 -(3-Chloro-4-methoxyphenyl)-3-(7-(2-fluoropyridin-3-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 17);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-fluoropyridin-4-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 18);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 19);
1 -(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 20);
1 -(5-Chloro-2-oxoindolin-7-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 21);
1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)urea (Compound 22);
1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(1,1-dioxidoisothiazolidin-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 23);
1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(1 H-1,2,3-triazol-1-yl)pyridin-3-yl)urea (Compound 24);
1 -(3-Chloro-4-methoxyphenyl)-3-(7-ethyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 25);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-ethyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 26);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4,4-difluoropiperidin-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 27);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-morpholinothiazolo[5,4-b]pyridin-6-yl)urea (Compound 28);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4-methoxypiperidin-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 29);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-methoxypiperidin-1 -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 30);

WO 2018/020474

PCT/IB2017/054612

343
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-ethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 31);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 32);
& 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 33);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1,2-dimethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 34);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropylthiazolo[5,4-3l b]pyridin-6-yl)urea (Compound 35);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 36);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(4-methylpiperidin-1-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 37);
5fe 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2,6-di methyl morphol in o)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 38);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2,6-dimethylmorpholino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 39);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(piperidin-1-tfn yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 40);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((cyclopropylmethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 41);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((cyclopropylmethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea tfe (Compound 42);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2,3-dimethoxypropyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 43);

WO 2018/020474

PCT/IB2017/054612

344
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2-methoxyethyl)(methyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 44);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxyethyl)(methyl)amino)-2-& methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 45);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1,3-dimethoxypropan-2-yl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 46);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2-(4-fluorophenyl)-2-methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea 3ft (Compound 47);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(2-methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 48);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclopropyl(2-methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 49);
^. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3-
(methoxymethyl)piperidin-l -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 50);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-(methoxymethyl)piperidin-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 51);
tin 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3-methoxypiperidin-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 52);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1-methoxypropan-2-yl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 53);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((1 -methoxypropan-2-tfe yl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 54);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxypropyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 55);

54612

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2,2-dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 56);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-2,2-dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 57);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3,6-dihydro-2H-pyran-4-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 58);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclohex-1-en-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 59);
1 -(5-Chloro-6-cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 60);
1-(5-Chloro-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 61);
1 -(5-Cyano-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 62);
1-(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 63);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 64);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 65);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1,4-oxazepan-4-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 66);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(1,4-oxazepan-4-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 67);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(cyclopropyl(2-methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 68);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclopropyl(2-nnethoxyethyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 69);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(cyclopropyl(2-methoxyethyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 70);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-hydroxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 71);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-fluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 72);
1 -(5-Chloro-6-(2-(1-methyl pi peridin-4-yl)eth oxy)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 73);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(dimethylamino)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 74);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-
(dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
75);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 76);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-(pyrrolidin-1-yl)ethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 77);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 78);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 79);
1-(7-(1-Methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 80);

1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 81);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 82);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 83);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 84);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-((4-fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 85);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-((4-fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 86);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-((4-fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 87);
1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 88);
1-(5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 89);
1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 90);
1-(5-Chloro-2-methoxy-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 91);
1-(5-Chloro-6-methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 92);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-cyclopropyl-1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 93);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-cyclopropyl-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 94);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-(2,2,2-trifluoro-1 -methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 95);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2-methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 96);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(2-methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 97);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(2-methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 98);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 99);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 100);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 101);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 102);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-(trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 1 03);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-(trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 1 04);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 105);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-(hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 106);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-(fluoromethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 107);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-((dimethylamino)methyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 108);
1 -(5-c hloro-2,4-dim ethoxy phenyl)-3-(7-(1-met hoxyethyl)-2-methyl thiazolo[5,4-b]pyridin-6-yl)urea (Compound 109);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(dimethylamino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 110);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(pyrrolidin-1-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 111);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-morpholinothiazolo[5,4-b]pyridin-6-yl)urea (Compound 112);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4,4-difluoropiperidin-1-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 113);
1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-(difluoromethyl)pyridin-4-yl)urea (Compound 114);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 115);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-ethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 116);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1 -methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 117);

1 -(3-chloro-4-methoxyphenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 118);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 119);
1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 120);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-(2-methoxyethoxy)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 121);
1 -(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 122);
1-(5-Chloro-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 123);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 124);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 125);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 126);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 127);
1 -(5-Chloro-2-methoxyphenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 128);
1 -(5-Cyanopyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 129);
1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-(trifluoromethyl)pyridin-4-yl)urea (Compound 130);

1-(5-Chloro-2-methoxy-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 131);
1-(5-Chloro-2-methoxy-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 132);
1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)urea (Compound 133);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 134);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 135);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 136);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 137);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 138);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 139);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 140);
1-(6-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 141);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 142);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 143);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 144);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 145);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 146);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 147);
1 -(5-Chloro-6-(5-methyloxazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 148);
1 -(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 149);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 150);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 151);
Methyl 3-chloro-5-(3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)ureido)benzoate (Compound 1 52);
1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 1 53);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 1 54);
1 -(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 1 55);

1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2-nnethylthiazolo[5,4-b]pyriclin-6-yl)urea (Compound 1 56);
1-(7-(sec-Butyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)urea (Compound 157);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 158);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 159);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 160);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 161);
1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 162);
1 -(3-Chloro-4-methoxyphenyl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 163);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 164);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 165);
1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 166);
1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 167);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 168);

1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 169);
1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(3,5-dichloro-4-(1H-1,2,3-triazol-1-yl)phenyl)urea (Compound 170);
1 -(3-Cyano-4-(3-methyl-1 H-1,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 171);
1 -(3-Cyano-4-(5-methyl-1 H-1,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 172);
1-(3-Chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 173);
1-(3-Chloro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 174);
1 -(5-Bromo-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 175);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(methoxymethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 176);
1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-(1-methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 177);
1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(1-methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 178);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 179);
1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-(1 -methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 180);
1 -(5-Chloro-6-(1 H-pyrazol-1 -yl)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 181);

1-(3-Chloro-4-(1 H-pyrazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 182);
1-(3-Chloro-4-(3-(methoxymethyl)-5-nnethyl-1H-pyrazol-1-yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 183);
1 -(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 184);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-(2-methoxyethoxy)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 185);
1 -(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 186);
1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 187);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 188);
1 -(5-Chlorothiophen-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 189);
1 -(5-Chlorothiophen-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 190);
1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 191);
1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 192);
1 -(3-Chloro-4-(difluoromethoxy)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 193);
1 -(5-Chloro-6-(1 -methyl-1 H-pyrazol-5-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 194);

1 -(5-Chloro-2-(2-(dimethylamino)ethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 195);
1-(5-Chloro-6-(1H-pyrazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 196);
1 -(5-Chloro-6-(isoxazol-4-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 197);
1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 198);
1 -(3-Chloro-4-(pyrazin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 199);
1-(5-Cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 200);
1-(3-Chloro-4-(1H-pyrazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 201);
1 -(3-Chloro-4-(pyrimidin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 202);
1-(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 203);
1-(3-Chloro-4-(oxazol-5-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 204);
1-(5-(Difluoromethyl)-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 205);
1-(5-(Difluoromethyl)-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 206);
1-(3-(Difluoromethyl)-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 207);

1-(3-Cyano-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 208);
1-(5-Chloro-2-methoxy-6-(1H-pyrazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 209);
1-(4-(1H-Pyrazol-1-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 210);
1-(3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 211);
1-(5-Fluoro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 212);
1-(6-(1H-Pyrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 213);
1 -(4-(Difluoromethoxy)-3-(trifluoromethyl)phenyl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 214);
1-(3-Chloro-4-(1H-imidazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 215);
1-(3-Chloro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 216);
1-(3-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 217);
1 -(5-Chloro-6-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 218);
1 -(5-Chloro-2-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 219);
1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-(methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 220);

1-(2-Ethoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 221);
1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-(trifluoromethyl)pyridin-3-yl)urea (Compound 222);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 223);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 224);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 225);
1 -(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-ethoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 226);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-
(dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound
227);
1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-
(cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 228);
1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(3,3-difluoroazetidin-1-yl)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (compound 229);
1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(dimethylamino)-2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 230);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(dimethylamino)-2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 231);
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-ethyl-7-(1-methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 232);
1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-ethyl-7-(1-methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 233);
1 -(6-((S)-2-Aminopropoxy)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea hydrochloride (Compound 234);
1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(((R)-1-methoxypropan-2-yl)(methyl)amino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 235);
1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(thiazol-2-ylamino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 236);
N-(5-(3-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)ureido)-3-(trifluoromethyl)pyridin-2-yl)acetamide (Compound 237);
1-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(methoxymethyl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 238);
1-(6-(1H-Tetrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 239); and
1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2-cyclopropyl-1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 240).
1 5. A pharmaceutical composition comprising a compound of any one of claims 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
16. A method for treating a disease or disorder mediated through MALT1 in a subject, comprising administering to the subject a therapeutically effective

amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.
17. The method of claim 16, wherein the said disease or disorder is cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.
18. The method of claim 17, wherein the said cancer is lymphoma or leukemia.
19. The method of claim 17, wherein the said cancer is ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1.
20. The method of claim 17, wherein the said cancer is germ cell tumors and neoplasm involving plasma cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney.
21. The method of claim 17, wherein said inflammatory disease or disorder is psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis, pancreatitis, rheumatic fever, or rheumatoid arthritis.
22. The method of claim 17, wherein said inflammatory disease or disorder is ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides.

23. The method of claim 17, wherein the said allergic or autoimmune disease or disorder is Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease.
24. The method of claim 17, wherein the said allergic or autoimmune disease or disorder is cystic fibrosis, respiratory diseases involving lungs leading to respiratory distress and failure.
25. The method of claim 24, whrein respiratory distress and failure means emphysema, pulmonary oedema, pulmonary embolism and primary pulmonary hypertension, and lung fibrosis due to Berylium poisoning.

26. Use of a compound of any one of claim 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorh thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or disorder mediated through MALT1 in a subject in need thereof.
27. The use as claimed in claim 26, wherein said disease or disorder is cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.
28. The use as claimed in claim 27, wherein the said cancer is lymphoma or leukemia.
29. The use as claimed in claim 27, wherein the said cancer is ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1.
30. The use as claimed in claim 27, wherein the said cancer is germ cell tumors and neoplasm involving plasma cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of

lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney.
31. The use as claimed in claim 27, wherein the said inflammatory disease or disorder is psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis, pancreatitis, rheumatic fever, or rheumatoid arthritis.
32. The use as claimed in claim 27, wherein said inflammatory disease or disorder is ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides.
33. The use as claimed in claim 27, wherein the said allergic or autoimmune disease or disorder is Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease.
34. The use as claimed in claim 27, wherein the said allergic or autoimmune disease or disorder is cystic fibrosis, respiratory diseases involving lungs leading to respiratory distress and failure.
35. The use as claimed in claim 34, whrein respiratory distress and failure means emphysema, pulmonary oedema, pulmonary embolism and primary pulmonary hypertension, and lung fibrosis due to Berylium poisoning.
36. A compound of any one of claims 1 to 14, a tautomer thereof, a
stereoisomer thereof, a polymorph thereof, a solvate thereof, or a
pharmaceutically acceptable salt thereof, for use in treating a disease or
disorder mediated through MALT1 in a subject in need thereof.